Osimertinib and anti-HER3 combination therapy engages immune dependent tumor toxicity via STING activation in trans

Jose Vicencio Bustamante*, Rachel Evans, R Green, Z An, Jinhai Deng, Conor Treacy, Rami Mustapha, James Monypenny of Pitmilly, C Costoya , K Lawler, K Ng, Karen Desouza, O Coban, V Gomez, J Clancy, SH Chen, A Chalk, F Wong, P Gordon, Courtney SavageC Gomes, T Pan, Giovanna Alfano, Luigi Dolcetti, Julie Nuo En Chan, F Florez-Borja , Paul Barber, Gregory Weitsman, D Sosnowska, E Capone, S Iacobelli, D Hochhauser, J Hartley, Madeline Parsons, James Arnold, Simon Ameer-Beg, Sergio A Quezada, Yosef Yarden, G Sala, Tony Ng

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

11 Citations (Scopus)
115 Downloads (Pure)

Fingerprint

Dive into the research topics of 'Osimertinib and anti-HER3 combination therapy engages immune dependent tumor toxicity via STING activation in trans'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science